TapewireFind a company

person · Reporting owner

LaBarre Michael J.

Disclosed activity across 1 company

Tapewire entity
82745
SEC CIK
0001507174

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
HALOZYME THERAPEUTICS, INC.HALO · Entity 793SVP, CHIEF TECHNICAL OFFICERFebruary 25, 2025February 27, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HALOZYME THERAPEUTICS, INC.

Report date February 25, 2025 · Filed February 27, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect173,756 Ending reported balance After 2025-02-27 transaction · row 6
6 source rows · reconciled sequence

Row 1 · 2025-02-25 · Sale · Disposed 9,300 · Balance 186,153

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 2 · 2025-02-25 · Sale · Disposed 700 · Balance 185,453

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 3 · 2025-02-26 · Sale · Disposed 9,400 · Balance 176,053

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 4 · 2025-02-26 · Sale · Disposed 600 · Balance 175,453

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 5 · 2025-02-27 · Sale · Disposed 1,597 · Balance 173,856

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 6 · 2025-02-27 · Sale · Disposed 100 · Balance 173,756

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 27, 2025 Filed Feb 27, 2025 23:32 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 100 $58.74 $5,874.00
Disclosure

SEC source: 0001415889-25-005899 · form4-02272025_110233.xml · nonDerivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,756

F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

Read SEC document
February 27, 2025 Filed Feb 27, 2025 23:32 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 1,597 $58.25 $93,028.44
Disclosure

SEC source: 0001415889-25-005899 · form4-02272025_110233.xml · nonDerivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,856

F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F6 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 26, 2025 Filed Feb 27, 2025 23:32 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 600 $58.65 $35,188.80
Disclosure

SEC source: 0001415889-25-005899 · form4-02272025_110233.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 175,453

F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F5 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 26, 2025 Filed Feb 27, 2025 23:32 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 9,400 $58.09 $546,055.40
Disclosure

SEC source: 0001415889-25-005899 · form4-02272025_110233.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 176,053

F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F4 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 23:32 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 700 $58.67 $41,069.00
Disclosure

SEC source: 0001415889-25-005899 · form4-02272025_110233.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 185,453

F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 23:32 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 9,300 $58.01 $539,465.10
Disclosure

SEC source: 0001415889-25-005899 · form4-02272025_110233.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 186,153

F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 23, 2025 Filed Feb 24, 2025 22:11 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionRestricted Stock Units · Derivative 4,747 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-25-005311 · form4-02242025_100257.xml · derivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,238

Underlying: Common Stock · 4,747 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Read SEC document
February 23, 2025 Filed Feb 24, 2025 22:11 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Tax withholdingCommon Stock 2,410 $57.75 $139,177.50
Disclosure

SEC source: 0001415889-25-005311 · form4-02242025_100257.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,453

F1 · shares: The reported disposition of 2,410 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

Read SEC document
February 23, 2025 Filed Feb 24, 2025 22:11 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 4,747 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-005311 · form4-02242025_100257.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,863

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 20, 2025 Filed Feb 21, 2025 23:52 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantRestricted Stock Units · Derivative 11,230 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-25-005177 · form4-02212025_110206.xml · derivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,230

Underlying: Common Stock · 11,230 shares

Expires not disclosed

F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

Read SEC document
February 20, 2025 Filed Feb 21, 2025 23:52 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantOption to Purchase Common Stock · Derivative 11,902 $0.00 Strike: $57.44 $0.00
Disclosure

SEC source: 0001415889-25-005177 · form4-02212025_110206.xml · derivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,902

Underlying: Common Stock · 11,902 shares

Expires 2035-02-20

F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter.

Read SEC document
February 16, 2025 Filed Feb 18, 2025 23:42 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionRestricted Stock Units · Derivative 4,263 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-25-004509 · form4-02182025_110228.xml · derivative · entry 12

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,526

Underlying: Common Stock · 4,263 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

F5 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Read SEC document
February 16, 2025 Filed Feb 18, 2025 23:42 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionRestricted Stock Units · Derivative 6,112 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-25-004509 · form4-02182025_110228.xml · derivative · entry 11

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,112

Underlying: Common Stock · 6,112 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

F5 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Read SEC document
February 16, 2025 Filed Feb 18, 2025 23:42 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionPerformance Stock Units · Derivative 20,891 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-25-004509 · form4-02182025_110228.xml · derivative · entry 10

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,891 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.

F6 · derivative.expiration_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.

Read SEC document
February 16, 2025 Filed Feb 18, 2025 23:42 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Tax withholdingCommon Stock 2,164 $58.29 $126,139.56
Disclosure

SEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 8

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 193,116

F4 · shares: The reported disposition of 2,164 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

Read SEC document
February 16, 2025 Filed Feb 18, 2025 23:42 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 4,263 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 7

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,280

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 16, 2025 Filed Feb 18, 2025 23:42 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Tax withholdingCommon Stock 3,103 $58.29 $180,873.87
Disclosure

SEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 191,017

F3 · shares: The reported disposition of 3,103 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

Read SEC document
February 16, 2025 Filed Feb 18, 2025 23:42 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 6,112 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,120

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 16, 2025 Filed Feb 18, 2025 23:42 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Tax withholdingCommon Stock 8,721 $58.29 $508,347.09
Disclosure

SEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 188,008

F2 · shares: The reported disposition of 8,721 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

Read SEC document
February 16, 2025 Filed Feb 18, 2025 23:42 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 20,891 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,729

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 15, 2025 Filed Feb 18, 2025 23:42 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionRestricted Stock Units · Derivative 3,386 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-25-004509 · form4-02182025_110228.xml · derivative · entry 9

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,386 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

F5 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Read SEC document
February 15, 2025 Filed Feb 18, 2025 23:42 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Tax withholdingCommon Stock 1,304 $58.29 $76,010.16
Disclosure

SEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,838

F1 · shares: The reported disposition of 1,304 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

Read SEC document
February 15, 2025 Filed Feb 18, 2025 23:42 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 3,386 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,142

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 23:12 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantPerformance Stock Units · Derivative 20,342 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-25-004243 · form4-02142025_110258.xml · derivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,342

Underlying: Common Stock · 20,342 shares

Expires not disclosed

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 23:12 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantPerformance Stock Unit · Derivative 4,921 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-25-004243 · form4-02142025_110258.xml · derivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,921

Underlying: Common Stock · 4,921 shares

Expires not disclosed

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 23:12 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantPerformance Stock Units · Derivative 4,177 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-25-004243 · form4-02142025_110258.xml · derivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,547

Underlying: Common Stock · 4,177 shares

Expires not disclosed

F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 23:12 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantPerformance Stock Units · Derivative 7,262 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-25-004243 · form4-02142025_110258.xml · derivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,891

Underlying: Common Stock · 7,262 shares

Expires not disclosed

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2022 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2022 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

Read SEC document
October 16, 2024 Filed Oct 16, 2024 22:53 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $19.98 $0.00
Disclosure

SEC source: 0001415889-24-025233 · form4-10162024_101045.xml · derivative · entry 9

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,608

Underlying: Common Stock · 10,000 shares

Expires 2030-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F5 · derivative.exercise_date: This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
October 16, 2024 Filed Oct 16, 2024 22:53 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $53.26 $532,590.00
Disclosure

SEC source: 0001415889-24-025233 · form4-10162024_101045.xml · nonDerivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,756

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $52.88 to $53.60. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 16, 2024 Filed Oct 16, 2024 22:53 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $19.98 $199,800.00
Disclosure

SEC source: 0001415889-24-025233 · form4-10162024_101045.xml · nonDerivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 183,756

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
October 15, 2024 Filed Oct 16, 2024 22:53 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 4,491 $0.00 Strike: $19.98 $0.00
Disclosure

SEC source: 0001415889-24-025233 · form4-10162024_101045.xml · derivative · entry 8

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,608

Underlying: Common Stock · 4,491 shares

Expires 2030-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F5 · derivative.exercise_date: This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
October 15, 2024 Filed Oct 16, 2024 22:53 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 5,509 $0.00 Strike: $16.65 $0.00
Disclosure

SEC source: 0001415889-24-025233 · form4-10162024_101045.xml · derivative · entry 7

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,352

Underlying: Common Stock · 5,509 shares

Expires 2029-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F4 · derivative.exercise_date: This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
October 15, 2024 Filed Oct 16, 2024 22:53 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 77 $54.25 $4,176.87
Disclosure

SEC source: 0001415889-24-025233 · form4-10162024_101045.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,756

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
October 15, 2024 Filed Oct 16, 2024 22:53 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 9,923 $53.74 $533,291.79
Disclosure

SEC source: 0001415889-24-025233 · form4-10162024_101045.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,833

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $53.24 to $54.22. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 15, 2024 Filed Oct 16, 2024 22:53 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 4,491 $19.98 $89,730.18
Disclosure

SEC source: 0001415889-24-025233 · form4-10162024_101045.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 183,756

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
October 15, 2024 Filed Oct 16, 2024 22:53 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 5,509 $16.65 $91,724.85
Disclosure

SEC source: 0001415889-24-025233 · form4-10162024_101045.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 179,265

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
September 18, 2024 Filed Sep 18, 2024 22:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $16.65 $0.00
Disclosure

SEC source: 0001415889-24-023657 · form4-09182024_100954.xml · derivative · entry 7

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,861

Underlying: Common Stock · 10,000 shares

Expires 2029-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F5 · derivative.exercise_date: This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
September 18, 2024 Filed Sep 18, 2024 22:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 2,037 $62.58 $127,477.50
Disclosure

SEC source: 0001415889-24-023657 · form4-09182024_100954.xml · nonDerivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,756

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F4 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $62.41 to $62.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
September 18, 2024 Filed Sep 18, 2024 22:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 7,963 $61.89 $492,838.03
Disclosure

SEC source: 0001415889-24-023657 · form4-09182024_100954.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 175,793

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $61.40 to $62.395. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
September 18, 2024 Filed Sep 18, 2024 22:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $16.65 $166,500.00
Disclosure

SEC source: 0001415889-24-023657 · form4-09182024_100954.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 183,756

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
September 17, 2024 Filed Sep 18, 2024 22:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $16.65 $0.00
Disclosure

SEC source: 0001415889-24-023657 · form4-09182024_100954.xml · derivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,861

Underlying: Common Stock · 10,000 shares

Expires 2029-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F5 · derivative.exercise_date: This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
September 17, 2024 Filed Sep 18, 2024 22:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $62.88 $628,780.00
Disclosure

SEC source: 0001415889-24-023657 · form4-09182024_100954.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,756

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $62.585 to $63.275. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
September 17, 2024 Filed Sep 18, 2024 22:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $16.65 $166,500.00
Disclosure

SEC source: 0001415889-24-023657 · form4-09182024_100954.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 183,756

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
August 27, 2024 Filed Aug 27, 2024 23:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 5,580 $0.00 Strike: $18.41 $0.00
Disclosure

SEC source: 0001415889-24-022363 · form4-08272024_110848.xml · derivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,580 shares

Expires 2028-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
August 27, 2024 Filed Aug 27, 2024 23:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 5,580 $18.41 $102,727.80
Disclosure

SEC source: 0001415889-24-022363 · form4-08272024_110848.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,756

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 21, 2024 Filed Aug 21, 2024 22:03 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $16.65 $0.00
Disclosure

SEC source: 0001415889-24-021850 · form4-08212024_100827.xml · derivative · entry 7

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,861

Underlying: Common Stock · 10,000 shares

Expires 2029-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F4 · derivative.exercise_date: This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
August 21, 2024 Filed Aug 21, 2024 22:03 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 100 $62.34 $6,234.00
Disclosure

SEC source: 0001415889-24-021850 · form4-08212024_100827.xml · nonDerivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,176

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
August 21, 2024 Filed Aug 21, 2024 22:03 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 9,900 $61.74 $611,235.90
Disclosure

SEC source: 0001415889-24-021850 · form4-08212024_100827.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,276

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $61.325 to $62.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 21, 2024 Filed Aug 21, 2024 22:03 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $16.65 $166,500.00
Disclosure

SEC source: 0001415889-24-021850 · form4-08212024_100827.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
August 20, 2024 Filed Aug 21, 2024 22:03 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $16.65 $0.00
Disclosure

SEC source: 0001415889-24-021850 · form4-08212024_100827.xml · derivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,861

Underlying: Common Stock · 10,000 shares

Expires 2029-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F4 · derivative.exercise_date: This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.